Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide

Krista Noonan, Scott North, Rhonda L. Bitting, +3

Annals of Oncology

UrologyOncologyAbiraterone AcetateMedicinePharmacotherapy +5

Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain

D. Scott Ernst, I. F. Tannock, Eric Winquist, +7

Journal of Clinical Oncology

Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group

Christina M. Canil, Malcolm J. Moore, Eric Winquist, +10

Journal of Clinical Oncology

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial

K.N. Chi, Shahneen Sandhu, Matthew R. Smith, +19

Annals of Oncology

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial

Cora N. Sternberg, Johann S. de Bono, K.N. Chi, +6

Annals of Oncology

UrologyOncologyElderly PatientsCancer ManagementClinical Trials +4

A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers

K.N. Chi, Evan Y. Yu, Cindy Jacobs, +7

Annals of Oncology

UrologyOncologyAntisense InhibitorMedicineImmune Checkpoint Inhibitor +5

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer

S. Chowdhury, Anders Bjartell, Neeraj Agarwal, +15

Annals of Oncology

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Vanessa Bernstein, Susan Ellard, Susan Dent, +16

Breast Cancer Research and Treatment

Metastatic Breast CancerBreast OncologyMedicineCancer ManagementPharmacology +7

Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)

Matthew R. Smith, Shahneen Sandhu, William Kevin Kelly, +15

Annals of Oncology

UrologyGenitourinary CancerMedicinePhase Ii StudyPre-specified Interim Analysis +4

Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study

Karin Oechsle, Friedemann Honecker, Tina Cheng, +10

Annals of Oncology

UrologyGenitourinary CancerMedicineMolecular OncologyCancer Treatment +4